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Background: There is increasing evidence for the role of microscopic inflammation in patients with IBS. We aimed
to examine the prevalence of microscopic colitis and inflammation in Malaysian IBS patients with diarrhoea (IBS-D).
Methods: Consecutive patients who met the Rome III criteria for IBS-D and asymptomatic controls were
prospectively recruited. Colonoscopy was performed in all study subjects and systematic biopsies taken from all
segments of the colon. The diagnosis of lymphocytic colitis and collagenous colitis was made using previously
defined criteria. Patients with post infectious IBS were excluded.
Results: 120 subjects (74 IBS-D, 46 controls) were recruited during the study period. In the IBS-D group, the
colonoscopic (macroscopic) findings were as follows; normal findings n = 58 (78.4%), diverticula disease n = 5 (6.8%),
diminutive polyps n = 9 (12.2%) and haemorrhoids n = 2(2.7%). No subject under the age of 40 had any significant
findings. Microscopically, there was only one case (1.3%) with histology consistent with collagenous colitis.
However, the IBS-D patients had a higher prevalence of moderate microscopic inflammation (n = 11, 14.9%)
compared to controls (n = 1, 2.2%) (p = 0.005).
Conclusions: ‘Classical’ microscopic colitis is uncommon in Malaysian patients with IBS-D but a significant number
of adults showed evidence of microscopic inflammation.Background
Irritable Bowel Syndrome (IBS) is defined as a chronic ab-
dominal discomfort associated with altered bowel habit. It
is a common gastrointestinal disorder worldwide, with
prevalence rates ranging from 2-22% in the West (depend-
ing on criteria used) [1] and a rate of 15% in the Malaysian
population, based on the Rome II criteria [2,3]. The Rome
criteria, the most recent modification being the Rome III
criteria [4], allows a positive diagnosis of IBS based on
symptoms alone and additionally allows for subtype classi-
fication depending on the predominant symptom. The
exact pathogenesis of IBS is generally unknown but postu-
lated mechanisms include alterations in gut motility,
visceral hypersensitivity, bacterial flora, together with* Correspondence: ida.hilmi@gmail.com
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reproduction in any medium, provided the orpsychological association [5-7]. Recently, there has been
an increased interest in the role of microscopic inflamma-
tion in patients with IBS [7-14].
‘Classical’ microscopic colitis is a histopathological
diagnosis which is currently accepted as an umbrella
term for either lymphocytic colitis or collagenous colitis.
Both subtypes share similar histological features, apart
from the fact that collagenous colitis has a significantly
thickened sub-epithelial collagen layer. The annual inci-
dence in western countries ranges from 1 to 12 per
100,000 and is a common finding (10-15%) in patients
investigated for chronic diarrhoea [15]. It is a disease of
the elderly with a strong female preponderance. The
pathogenesis is not fully elucidated but autoimmunity,
luminal antigens, drugs such as NSAIDs and bile salt
malabsorption have been implicated [15]. The clinical
symptoms include chronic diarrhoea, urgency, incontin-
ence, anorexia, nausea, abdominal cramping, and mildtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients who have microscopic colitis also fulfill the Rome
criteria for IBS [16-18]. Therefore, a subset of IBS pa-
tients, in particular those with diarrhoea (IBS-D) who do
not undergo colonoscopy and biopsies would have
missed a diagnosis of microscopic colitis. This is clinic-
ally relevant as there is effective treatment, in particular
budesonide, which has been specifically licensed for this
condition [15,19-22]. In addition, a diagnosis of micro-
scopic colitis should prompt a search for associated
autoimmune conditions such as coeliac disease.
As IBS represents a significant health problem in
Malaysia, the aim of this study was to examine the
prevalence of microscopic colitis in Malaysian patients
with IBS-D. In view of the increasing evidence for the
role of inflammation in patients with IBS, our secondary
objective was to examine the histopathological features
in these patients compared to controls.
Methods
This study was approved by the University of Malaya
Medical Centre (UMMC) Ethics Committee. Consecutive
patients who presented to the UMMC Endoscopy Unit,
who met the Rome III criteria for IBS-D from May 2010
to May 2011, were prospectively recruited following in-
formed consent. These patients were primarily referred
from primary care physicians for further investigation, and
none had undergone prior colonoscopy. In our clinical
practice, a colonoscopy is usually requested after a nega-
tive screen for organic causes of diarrhoea such as para-
sitic infestation, thyroid disease, etc. However, screening
for Coeliac Disease and Tropical Sprue are not routinely
performed as they are rare in our population. The controls
chosen during the same time period were asymptomatic
subjects who had undergone colonoscopy for colorectal
cancer screening or polyp surveillance. Subjects with the
following features were excluded: prior gastrointestinal
surgery, significant loss of weight, bloody stool, metabolic
disorders such as thyrotoxicosis, corticosteroid usage in
the past 4 weeks and those with a recent GI infection (i.e.
indicative of post-infectious IBS).
Baseline demographic characteristics, detailed GI symp-
toms, smoking history, alcohol intake, drug history and
concomitant medical illness were documented. A single
stool sample from each patient was sent for microscopy
and culture.
Colonoscopy and biopsy
For all subjects, the bowel preparation used was polyethyl-
ene glycol (Fortrans®). During colonoscopy, the macro-
scopic findings were recorded. Two well-oriented biopsies
were taken from each part of the colon (i.e. caecum, as-
cending colon, transverse colon, descending colon, sigmoid,
and rectum) which appeared macroscopically normal. Thebiopsies were fixed in 10% buffered formalin and sent for
processing. The tissues were routinely processed for light
microscopic examination. The paraffin embedded biopsy
materials were sectioned and stained with the Hematoxylin
and eosin stain. Additional stains such as Masson tri-
chrome stains for collagen fibres were done when collage-
nous colitis was suspected on H&E stains.
Histopathological assessment
Biopsy specimens were assessed by an experienced path-
ologist who was blinded to the clinical indication for
colonoscopy. Quantitative assessment of intraepithelial
lymphocytes, intraepithelial neutrophils, subepithelial
collagen thickness, and lamina propria infiltration (by lym-
phocytes, plasma cells, and mononuclear cells) were docu-
mented as well as the presence of crypt distortion and
surface epithelial damage. The histological criteria for the
diagnosis of lymphocytic colitis was as follows; increased
intraepithelial lymphocytes (IEL) of 20 or more per 100
epithelial cell in conjunction with surface epithelial dam-
age, normal collagen layer and normal crypt architecture.
The histological criteria for collagenous colitis was abnor-
mally thickened subepithelial collagen band of 10 μm or
more, chronic inflammation including increased IEL and
normal crypt architecture [23].
Results
Demography
One hundred and twenty subjects, 74 who fulfilled the
Rome III criteria and 46 controls were recruited. The
demography of both cases (IBS-D patients) and controls
are highlighted in Table 1. Among IBS-D patients, the
male:female ratio was 1:1.4, and the median age was
51 years. The median stool frequency was 4 times per
day (range 2–10), the median duration of symptoms was
12 months and nocturnal diarrhoea was seen in 3 (4%)
subjects. In the control group, the male:female ratio was
1:0.9, and the median age was 62 years.
Colonoscopy findings
The colonoscopy (macroscopic) findings in the IBS-D
group were as follows; normal findings n = 58 (78.4%),
diverticula disease n = 5 (6.8%), diminutive polyps n = 9
(12.2%) and haemorrhoids n = 2(2.7%). No subject under
the age of 40 had any significant findings. Colonoscopy
findings in the control group were as follows: normal
findings n = 27(58.7%), adenomas n = 15(32.6%) (one
large rectal polyp 1 cm, the others <1 cm), diverticula
disease n = 3(6.5%) and haemorrhoids n = 1(2.2%).
Histological findings
Collagenous colitis was diagnosed in a single, 63-year
old female IBS-D patient, of Indian ethnicity. The
histological features of thickened collagen fibres were
Table 1 Summary of baseline characteristics, endoscopic
and histological findings in patients with IBS-D and
controls
IBS-D n(%) Controls n(%)
Total 74 Total 46
Gender Gender
Male 31(41.9%) Male 24(52.2%)
Female 43(58.1%) Female 22(47.8%)
Median age(years) 51(16–78) Median(range) 61(26–79)
Race Race
Malay 15(20.3%) Malay 8(17.4%)
Chinese 36(48.6%) Chinese 31(66%)
Indian 23(31.1%) Indian 7(14.9%)
Colonoscopic findings Colonoscopic findings
Normal 58 (78.4%) Normal 27(58.7%)
Polyps 9 (12.2%) Polyps 15(32.6%)
Diverticular disease 5 (6.8%) Diverticular disease 3(6.5%)
Haemorrhoids 2(2.7%) Haemorrhoids 1(2.2%)
Histological findings Histological findings
Normal 62(83.8%) Normal 0(97.8%)
Collagenous 1(1.4%) Collagenous colitis 0(0)
Lymphocytic colitis 0(0%) Lymphocytic colitis 0(0)
Non specific colitis 11(14.9%) Non specific colitis 1(2.2%)
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and rectum (Figure 1). There were no subjects who ful-
filled the criteria for lymphocytic colitis.
A further 11/74 (14.9%) IBS-D cases showed evidence of
microscopic inflammation, with moderate lymphocytic
and plasmacytic infiltration in the lamina propria. Eight
cases had distal involvement but in four cases, inflamma-
tion was seen only proximal to the splenic flexure only. In-
filtration of an occasional crypt by neutrophils was seen inFigure 1 IBS-D patient with collagenous colitis. Note the
thickened collagen band (arrow).five of the cases and scattered crypt abscesses in the trans-
verse colon, sigmoid colon and rectum were present in
one case. Moderate infiltration of the lamina propria only
without crypt involvement was noted in the remaining five
cases. An example of one of the cases is seen in Figure 2.
The remaining 62 (83.7%) subjects with IBS-D did not
show any evidence of significant inflammation throughout
the colon (Figure 3).
Amongst those in the control group, moderate infiltra-
tion of lymphocytes in the ascending and transverse colon,
with no evidence of cryptitis, was found in 1/46 (2.2%)
adult. This patient was an asymptomatic, 60-year-old
Chinese male, who had undergone a colonoscopy for colo-
rectal cancer screening. None of the other subjects in the
control group showed any evidence of significant micro-
scopic inflammation. Univariate analysis demonstrated
that IBS-D subjects, compared to controls, had a greater
prevalence of moderate to severe microscopic inflam-
mation (14.9% vs 2.2%, OR 11.44, 95% CI = 1.49-240.69,
p = 0.005).
Discussion
There are several relevant observations in our study. The
primary objective was to look at the prevalence of micro-
scopic colitis in patients who were diagnosed with IBS-D
as defined by the Rome III criteria. From the study, it
appears that classic microscopic colitis is very uncommon
in our cohort of patients with IBS-D. However, a signifi-
cant percentage of subjects with IBS-D had evidence of
microscopic inflammation that did not fit the criteria for
classical microscopic colitis. The most common abnor-
malities seen were mixed chronic and acute inflammatory
cells, lymphocytes, plasma cells and neutrophils; with or
without cryptitis and crypt abscesses.
The categories of microscopic colitis were recently ex-
panded by Falodia et al. into five subtypes: collagenousFigure 2 IBS -D patient with evidence of moderate to severe
inflammation on histology.
Figure 3 IBS-D patient with normal histology.
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architectural abnormality in the form of cryptitis and
crypt dilatation in the absence of increase in intra-
epithelial lymphocytes and subepithelial collagenous
band), microscopic colitis not otherwise specified (in-
creased inflammatory cell infiltrates in the lamina
propria in the absence of other abnormalities) and
microscopic colitis with giant cells [24]. If we were to
reclassify our patients according to the above categories,
one patient had collagenous colitis, six patients had
minimal change colitis and five patients had microsopic
colitis not otherwise specified. However, the classifica-
tion proposed by Falodia et al. has yet to be widely ac-
cepted and the therapeutic studies carried out in the
past only looked specifically at collagenous and lympho-
cytic colitis. Inflammation was patchy throughout the
colon and from the study, four cases showed inflamma-
tion beyond the splenic flexure. This is similar to clas-
sical microscopic colitis, where the diagnosis can be
missed unless a complete colonoscopy with biopsies
throughout the colon is conducted [15].
The role of inflammation in IBS has been of interest in
recent times and evidence of low level inflammation has
been demonstrated in both post infectious and non-post
infectious IBS. Gwee et al. found increased expression of
pro-inflammatory cytokine interleukin Iβ (IL-1β) mRNA
in subjects with post-infectious IBS, which was not
observed in adults without IBS [12]. Chadwick et al.
[25,26] had divided the histological findings of IBS pa-
tients into three groups; those with normal histology,
those with evidence of microscopic inflammation and
those who met criteria for lymphocytic colitis. With im-
munostaining, it was found that all three groups had in-
creased numbers of activated immunocompetent cells in
the intestinal mucosa. Barbara et al. [27] reported that
increased numbers of activated mast cells in closeproximity to intestinal innervation correlated with ab-
dominal pain in IBS. In addition to this, there is evi-
dence that patients with IBS-D have an increased
expression of TNFα and IL-1β in the peripheral blood
monocytes, not dissimilar to that found in patients with
inflammatory bowel disease [8]. A study from Sri Lanka
also showed low grade inflammation in IBS patients, simi-
lar to Western studies but with an increase in eosinophils
as well as the other chronic inflammatory cells [28].
An attractive concept is that IBS-D forms the mildest
part of a disease spectrum, with idiopathic inflammatory
bowel disease (in particular, ulcerative colitis) at the other
end, with classical microscopic colitis in between [29,30].
There is a clear overlap in terms of their proposed patho-
genesis including alterations in intestinal microbiota and
bile salt malabsorption. However, the common pathways
between the conditions remain poorly understood and the
majority of IBS-D patients fail to demonstrate significant
inflammation on histology.
In the light of Western studies demonstrating a signifi-
cant overlap between classical microscopic colitis and
IBS-D, as well as the increasing role of inflammation in
IBS patients, ‘to do or not to do’ colonoscopy in patients
with IBS-D remains as unclear as ever. Although the sin-
gle case of collagenous colitis in our study was found in
the ‘typical’ subject (elderly, female), non specific inflam-
mation was seen in both age groups, both genders and
across all three races. As the prevalence of collagenous
and lymphocytic colitis appears to be low in our popula-
tion, routine colonoscopy is not justified in young pa-
tients who have been identified as IBS on symptom
based criteria. This may change however, in light of
promising data on the use of anti-inflammatory drugs
such as mesalazine in IBS [31-34]. It is uncertain, how-
ever, if only those with evidence of microscopic in-
flammation will respond to anti-inflammatory therapy,
thereby necessitating the use of routine colonoscopy in
order to provide a more individualised approach to the
management of these patients.
The low colonoscopic yield among IBS patients in this
study is noteworthy. No macroscopic abnormalities were
seen in subjects under the age of forty and it is also re-
assuring to note that no significant pathology was identi-
fied in the older adults. In fact, our findings were very
similar to a large study carried out in USA where find-
ings of polyps, diverticular disease and haemorrhoids in
subjects with IBS were no different to that of asymptom-
atic controls [35]. While it is certainly reasonable to still
offer colonoscopy in older patients with IBS for colorec-
tal cancer screening, the study emphasizes the import-
ance of careful history taking in stratifying patients who
do or do not require colonoscopy and those who require
it urgently or otherwise. This is especially relevant in
Malaysia, which is still considered a developing country,
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gastroenterologists in a population of 25 million [36].
There are several limitations of the study. The study
sample was small and patients were derived from sec-
ondary care, which may not be representative of IBS pa-
tients in the community. As IBS, like other functional
GI diseases, is rarely life-threatening, medical consult-
ation rates amongst sufferers are known to be low. CD3
staining for lymphocytes was not carried out which may
have resulted in an under-diagnosis of lymphocytic col-
itis [37]. Screening for Coeliac Disease, rare among our
population but known to be associated with collagenous
colitis, was not performed. However, the merits of this
study lay in our strict adherence to the Rome III criteria
and systematic sampling of colonic mucosal tissue, pro-
viding an accurate estimation of inflammation in an
Asian population with IBS-D.
Conclusions
In this prospectively conducted study, we have found a
significant proportion of patients with IBS-D who have
evidence of colonic inflammation on biopsies which may
be part of a microscopic colitis spectrum. This further
adds to the growing evidence for the role of inflamma-
tion which will hopefully result in increasing the thera-
peutic options for the management of this common but
difficult to treat condition.
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